OSTM1-related autosomal recessive osteopetrosis is a very rare, inherited bone disease. It happens when a child inherits two non-working copies of a gene called OSTM1. This gene helps special bone cells, called osteoclasts, do their job: gently “eat” old bone so that fresh, healthy bone can replace it. When OSTM1 does not work, osteoclasts cannot clear old bone. As a result, bones become abnormally dense but also brittle and easy to break. The heavy, crowded bone marrow space can also fail to make enough blood cells, and nerves may be squeezed as they pass through narrow bone canals. OSTM1 disease is often one of the most severe forms of infantile osteopetrosis and can also affect the brain and nerves, causing developmental delay, seizures, and vision or hearing loss. BioMed Central+2PubMed+2
OSTM1-related ARO is a severe infantile form of osteopetrosis caused by harmful variants in the OSTM1 gene. OSTM1 forms a functional complex with the chloride channel CLC-7 in lysosomes and osteoclasts; without it, osteoclasts cannot acidify the bone surface and bone resorption fails, producing very dense but brittle bone. What makes OSTM1 unique is its frequent, early, and severe neurologic involvement, which drives disability and early mortality compared with other ARO genotypes. ScienceDirect+2MDPI+2
Babies typically present in the first months of life with poor growth, anemia or low platelets from bone-marrow crowding, recurrent infections, and compressive cranial neuropathies (vision and hearing loss). In OSTM1 disease, progressive neurodegeneration is common and strongly worsens outcomes; several cohorts describe OSTM1 ARO as a particularly severe subtype with CNS involvement and poor prognosis. PubMed+2ScienceDirect+2
Researchers estimate that OSTM1 changes cause roughly ~4–5% of autosomal recessive osteopetrosis cases worldwide, but they are often among the most severe, with early-life symptoms and frequent central nervous system (CNS) involvement. NCBI+1
Other names
Autosomal recessive osteopetrosis type 5 (ARO5 / OPTB5; OMIM 259720) – the historical “type number” used in genetics catalogs. PubMed
Malignant infantile osteopetrosis due to OSTM1 – highlights early, severe presentation in babies. BioMed Central
Infantile osteopetrosis with neuroaxonal dystrophy – used when brain and nerve degeneration are prominent. Orpha.net
OSTM1 deficiency or osteoclastogenesis-associated transmembrane protein-1 (OSTM1)–related osteopetrosis – describes the gene/protein involved. MDPI
Types
Strictly speaking, OSTM1 disease is one genetic type within the broader group of autosomal recessive osteopetrosis. Clinicians, however, often describe phenotypic subtypes by severity and neurological involvement:
Classic infantile malignant OSTM1-ARO – presents in early infancy with very dense bones, anemia, low platelets, enlarged liver/spleen, and fractures. BioMed Central
Neuronopathic OSTM1-ARO – same bone findings, plus clear brain/nerve involvement (developmental delay, seizures, visual impairment), reflecting OSTM1’s role in neurons as well as osteoclasts. ScienceDirect+1
Post-transplant OSTM1-ARO – children who receive hematopoietic stem-cell transplant (HSCT) may improve bone and blood features, but neurological issues may persist because OSTM1 also acts in the brain. PMC
Causes
Because this condition is monogenic, the root cause is biallelic (two-copy) pathogenic variants in the OSTM1 gene. Below are 20 clear “cause or driver” statements that explain mechanisms and clinical aggravators within that single-gene framework.
Loss-of-function OSTM1 variants (nonsense/frameshift) remove or truncate the protein, disabling osteoclast bone resorption. OUP Academic
Missense OSTM1 variants can destabilize the protein or its trafficking, weakening osteoclast function. MDPI
Defective OSTM1–CLCN7 complex support – OSTM1 is critical for the chloride channel CLCN7; loss disrupts the acidic environment osteoclasts need to dissolve bone. MDPI
Impaired lysosomal function in osteoclasts leads to poor ruffled-border formation and failed bone resorption. MDPI
Neuronal OSTM1 roles – OSTM1 is also needed in neurons; loss contributes to neurodegeneration and seizures. PubMed
Reduced bone marrow space from dense bone crowds blood-forming cells, causing anemia and low platelets. BioMed Central
Cranial nerve canal narrowing squeezes optic and auditory nerves, worsening vision/hearing. Medscape
Hypocalcemia from impaired bone remodeling may trigger muscle twitching or seizures in infants. BioMed Central
Pathological micro-architecture – dense but brittle bone increases fracture risk with minor trauma. Medscape
Dental eruption failure due to abnormal bone remodeling around tooth buds. BioMed Central
Recurrent infections from marrow failure (low white cells) and sometimes postsplenectomy states. BioMed Central
Growth failure driven by chronic illness, marrow failure, and nutrition challenges. NCBI
Raised intracranial pressure from narrowed skull foramina and abnormal skull thickening. BioMed Central
Bone pain and irritability from high skeletal pressure and micro-fractures. PMC
Osteomyelitis risk (especially jaw) because brittle bone and dental problems invite infection. preventiongenetics.com
Anemia-related hypoxia can worsen development and fatigue. BioMed Central
Platelet deficiency increases bleeding and bruising risk. BioMed Central
Vision loss due to optic nerve compression and retinal/neuronal effects. Medscape
Hearing loss from auditory nerve compression or middle-ear changes. Medscape
Early mortality in severe cases because of marrow failure, infections, neurologic decline, or complications without effective treatment. PubMed
Symptoms
Frequent fractures after mild falls because bone is dense but fragile. Medscape
Pale skin, tiredness, fast breathing from anemia. BioMed Central
Easy bruising or nosebleeds from low platelets. BioMed Central
Big liver and spleen (hepatosplenomegaly) as the body tries to make blood outside the marrow. BioMed Central
Poor weight gain and short stature due to chronic illness. NCBI
Large head or heavy skull bones on exam or imaging. BioMed Central
Vision problems (reduced vision, nystagmus) from optic nerve compression. Medscape
Hearing loss from nerve compression or middle-ear issues. Medscape
Delayed tooth eruption, dental infections, jaw pain. BioMed Central
Bone pain and irritability, especially in infants. PMC
Developmental delay due to CNS involvement. PubMed
Seizures (sometimes also linked to low calcium). PubMed
Recurrent infections because of marrow failure. BioMed Central
Constipation or feeding difficulty in infants under stress from illness. (Common in severe infant disorders; often reported anecdotally alongside failure to thrive in ARO cohorts.) BioMed Central
Headache or vomiting from raised intracranial pressure. BioMed Central
Diagnostic tests
A) Physical examination
General exam and growth charting – checks weight/length/head size and looks for pallor, bruises, and enlarged liver/spleen; helps stage severity. BioMed Central
Neurologic exam – checks muscle tone, reflexes, development, and seizures to detect CNS involvement. PubMed
Eye exam (fundoscopy/visual behavior) – looks for optic nerve swelling/pallor and functional vision. Medscape
Ear and cranial nerve checks – screens hearing and facial nerve function. Medscape
Dental/oral exam – identifies delayed eruption, caries, and jaw tenderness suggesting osteomyelitis. BioMed Central
B) “Manual” bedside/office tests
Transillumination and head circumference trend – simple bedside methods to flag skull thickening and raised pressure risk over time. BioMed Central
Hand-grip or age-appropriate motor tasks – practical screens for weakness from nerve compression or anemia. Medscape
Developmental screening tools – structured checklists to document delay. PubMed
Bedside hearing/vision screens – quick checks that guide formal testing. Medscape
Pain scales/irritability diaries – track bone pain and comfort, especially for infants. PMC
C) Laboratory and pathology tests
Complete blood count (CBC) – often shows anemia and thrombocytopenia from marrow failure. BioMed Central
Blood film and reticulocyte count – assess bone-marrow output and cell morphology. BioMed Central
Serum calcium, phosphate, alkaline phosphatase, PTH, vitamin D – documents mineral balance; hypocalcemia may appear. BioMed Central
Genetic testing (OSTM1 sequencing/panels) – definitive for diagnosis; looks for biallelic pathogenic variants. preventiongenetics.com
Bone marrow exam (select cases) – shows marrow crowding; osteoclasts may be present but dysfunctional. BioMed Central
D) Electrodiagnostic tests
Electroencephalogram (EEG) – evaluates seizures and background brain activity. PubMed
Auditory brainstem response (ABR) – measures hearing pathway function when nerve compression is suspected. Medscape
Visual evoked potentials (VEP) – tests optic pathway function to quantify vision risk. Medscape
E) Imaging tests
Skeletal survey (plain X-rays) – hallmark finding is diffuse bone sclerosis (dense bones), “bone-within-bone,” and end-plate changes. BioMed Central
CT of temporal bone/skull base – evaluates optic and auditory canal narrowing. Medscape
Brain MRI – looks for white-matter changes, hydrocephalus/pressure signs, or neuroaxonal dystrophy. ScienceDirect
Spine and pelvis imaging – assesses marrow space and fracture risk. BioMed Central
Dental panoramic X-ray – shows delayed tooth eruption and jaw bone changes. BioMed Central
DEXA is generally not helpful (bones look “strong” by density but are fragile); the diagnosis relies on radiographic patterns and genetics, not DEXA scores. BioMed Central
Ultrasound (abdomen) – checks liver/spleen size for extramedullary hematopoiesis. BioMed Central
Non-pharmacological treatments (therapies & other supports)
These measures aim to reduce complications, preserve function, and improve quality of life. They do not alter the underlying OSTM1 biology but are central to day-to-day care.
Early multidisciplinary care. Assemble a team (pediatrics, hematology, neurology, ophthalmology/ENT, dentistry, nutrition, PT/OT) in the first months of life. Coordinated surveillance catches marrow failure, infections, and cranial nerve compression early, which is vital in OSTM1 disease given rapid neurologic progression. OUP Academic+1
Infection prevention protocols. Strict hand hygiene, prompt evaluation of fevers, immunization per schedule (including influenza), and early antibiotics for suspected bacterial infections; marrow crowding predisposes to cytopenias and infections. OUP Academic
Low-vision preservation & habilitation. Regular ophthalmology checks for optic canal compression and retinal issues; fit low-vision aids and teach visual habilitation strategies to maximize residual vision. Consider timely referral for decompression only when clearly indicated (see surgeries section). OUP Academic
Hearing support. Serial audiology because osseous overgrowth can narrow auditory canals; early fitting of hearing aids or assistive tech improves language and development. OUP Academic
Nutritional optimization. Individualized pediatric nutrition to support growth despite high illness burden; avoid excessive calcium or vitamin D without supervision because they can worsen hypercalcemia or calcifications in some scenarios. OUP Academic
Physical therapy (PT). Gentle range-of-motion, posture, and core-strength routines adapted for fragile, dense bones help maintain mobility and reduce contractures; avoid high-impact maneuvers due to fracture risk. OUP Academic
Occupational therapy (OT). Daily-living skills training; adaptive tools to compensate for visual/hearing impairment and fine-motor challenges common in neurodegenerative forms. OUP Academic
Fracture prevention & safe handling. Teach caregivers safe lifting/positioning; use supportive seating and protective gear for high-risk activities; address home hazards. OUP Academic
Dental/craniofacial care. Proactive dental hygiene and early treatment of infections; osteopetrosis predisposes to osteomyelitis of the jaw, so prevention and conservative care are crucial. OUP Academic
Anemia & bleeding surveillance. Frequent CBC monitoring for marrow failure; timely transfusion support and referral to hematology when hemoglobin or platelets drop. OUP Academic
Neurologic monitoring. Track development, tone, seizures, and neuropathic pain; address spasticity and sleep disturbance early to preserve comfort and function in the face of progressive CNS disease. ScienceDirect
Pain management plan. Structured, stepwise pain plan including non-drug strategies (positioning, warm/cold packs, therapy modalities); integrate neuropathic-pain assessment tools due to nociplastic components reported in OSTM1 ARO. Wiley Online Library
Vision/education support. Early-intervention programs, individualized education plans, and assistive technologies (large-print, audio) help counter developmental impacts of sensory loss. OUP Academic
Bone-safe mobility aids. Properly sized strollers, braces, or walkers that reduce falls while minimizing localized pressure on fragile bones. OUP Academic
Caregiver training & respite. Teach red flags (fever, seizures, unusual drowsiness, decreased intake) and provide access to respite and social work support; chronic, complex care is demanding. OUP Academic
Vaccination adherence. Follow national schedules; live vaccines may still be appropriate unless contraindications exist—coordinate with the specialist team, particularly if immunosuppression is considered for complications. OUP Academic
Bone-marrow failure planning. Establish thresholds and workflows for transfusions and antibiotics; pre-arrange local hospital pathways to speed care during infections or bleeding. OUP Academic
Sleep & respiratory support. Screen for sleep-disordered breathing if craniofacial structures narrow airways; non-invasive support can improve energy and development. OUP Academic
Palliative/complex care integration. Introduce pediatric palliative care early to optimize symptom control and family support—especially important in OSTM1 ARO given progressive neurologic disease. ScienceDirect
Shared decision-making about HSCT. Discuss benefits vs. risks honestly: while HSCT can help other ARO forms, OSTM1 patients often continue to deteriorate neurologically even after early transplant. Decisions should integrate genotype, neurologic status, and family values. PMC+1
Pharmacologic treatments
Important: As of today, the only FDA-approved therapy specifically for malignant infantile osteopetrosis is interferon gamma-1b (ACTIMMUNE®), and its effect is to delay disease progression—it is not curative. Other medicines below are supportive/off-label and target complications (seizures, infections, anemia, etc.); I cite FDA labels for authoritative dosing/safety information, even though these drugs are not approved for osteopetrosis itself. FDA Access Data+1
Interferon gamma-1b (ACTIMMUNE®).
Class: Cytokine (immune modulator).
Dose/Timing (per label): 50 mcg/m² subcutaneously three times weekly (e.g., Monday/Wednesday/Friday).
Purpose/Mechanism: Approved to delay time to disease progression in severe malignant osteopetrosis; IFN-γ enhances macrophage/osteoclast function and may improve marrow space and infection resistance.
Side effects: Fever, fatigue, injection-site reactions; cytopenias and liver enzyme elevations can occur—monitor CBC and LFTs.
Evidence: FDA label + clinical experience; non-infantile pilot data show safety/tolerability. FDA Access Data+2FDA Access Data+2Broad-spectrum antibiotics (e.g., ceftriaxone) for serious bacterial infections.
Class: Third-generation cephalosporin.
Dose/Timing: Per standard pediatric sepsis/serious infection protocols.
Purpose/Mechanism: Treats severe infections in cytopenic or immunologically stressed patients.
Side effects: Allergy, diarrhea, biliary sludging (rare).
Evidence: Standard infectious-disease practice (antibiotic choice per culture/local guidelines) within osteopetrosis management frameworks. OUP AcademicOral antibiotics for ENT/dental infections (e.g., amoxicillin–clavulanate).
Class: Penicillin + β-lactamase inhibitor.
Purpose/Mechanism: Target common head-and-neck pathogens to prevent jaw osteomyelitis, a known osteopetrosis risk.
Risks: Allergy, GI upset, candidiasis; stewardship is essential. OUP AcademicAnticonvulsants (e.g., levetiracetam) for seizure control.
Class: Antiepileptic.
Purpose/Mechanism: Controls seizures from hypocalcemia or CNS disease.
Side effects: Somnolence, irritability; dosing per pediatric label. OUP AcademicAnalgesics for pain (acetaminophen; careful opioid use if necessary).
Purpose/Mechanism: Reduce nociceptive and neuropathic pain; tailor to severity and comorbidities.
Risks: Hepatotoxicity with acetaminophen overdose; opioid adverse effects. Wiley Online LibraryRed-cell and platelet transfusions.
Purpose/Mechanism: Support marrow failure from medullary cavity obliteration; transfusion thresholds individualized.
Risks: Transfusion reactions, alloimmunization; managed by hematology. OUP AcademicErythropoiesis-stimulating agents (ESAs) in select cases.
Purpose/Mechanism: May reduce transfusion needs in chronic anemia when appropriate.
Caveat: Off-label in ARO; use by hematology only. OUP AcademicCalcium and magnesium repletion for acute hypocalcemic symptoms.
Purpose/Mechanism: Treats tetany/seizures when hypocalcemia occurs (e.g., postoperative or illness-related).
Caveat: Avoid chronic excess calcium; tailor to labs. OUP AcademicVitamin D or calcitriol under specialist oversight.
Purpose/Mechanism: Corrects deficiency; does not reverse ARO and high-dose regimens can be counterproductive according to translational data.
Note: Not disease-modifying in ARO; careful monitoring required. PubMedGranulocyte-colony-stimulating factor (G-CSF) for severe neutropenia, if present.
Purpose/Mechanism: Shortens neutropenia duration, potentially reducing infection risk.
Use: Specialist-directed and individualized. OUP Academic
Beyond interferon-γ, there are no additional FDA-approved drugs for osteopetrosis itself, and listing 20 medicines risks implying evidence that doesn’t exist for OSTM1 ARO. The remaining medical care is tailored, off-label, and best guided by the specialist team and consensus guidelines. FDA Access Data+1
Dietary molecular supplements
There is no evidence that supplements change OSTM1 disease biology, but some may help general health or symptom control when tailored to labs and nutrition status. Always involve the clinical team.
Standard vitamin D (deficiency replacement only). Supports bone/mineral balance when deficient; avoid high chronic doses that could worsen hypercalcemia. OUP Academic+1
Omega-3 fatty acids. May aid general cardiovascular and anti-inflammatory balance; neutral for bone disease itself. OUP Academic
Vitamin K (dietary intake). Ensures normal coagulation and bone protein carboxylation; supplement only if deficient. OUP Academic
Iron (if iron-deficiency anemia). Corrects iron-deficit–related anemia; monitor ferritin and transferrin saturation with hematology. OUP Academic
Folate/B12 (if deficient). Supports erythropoiesis; check levels before supplementing. OUP Academic
Magnesium. Helps stabilize calcium–magnesium balance and neuromuscular excitability; replace only if low. OUP Academic
Zinc (if low). Supports growth, appetite, and immune function; avoid excess. OUP Academic
Probiotics (case-by-case). May reduce antibiotic-associated diarrhea; avoid in severely immunocompromised states. OUP Academic
Multivitamin at RDA levels. Helps cover gaps in selective eaters; avoid megadoses of fat-soluble vitamins. OUP Academic
Protein/energy supplements. Pediatric formulas to maintain growth when oral intake is marginal. OUP Academic
Immunity-booster / regenerative / stem-cell concepts
There are no proven immune-boosting pills for OSTM1 ARO. Below are realistic, clinician-directed approaches that may improve physiology or manage complications; none replace disease-modifying therapy.
Interferon gamma-1b (immune modulation). Enhances macrophage/osteoclast activity; FDA-approved for SMO to delay progression, with monitoring for cytopenias and liver effects. FDA Access Data+1
Nutritional immune support. Correct overt deficiencies (iron, zinc, vitamins A/D/B complex) to normalize host defense—avoid megadoses. OUP Academic
Vaccination-based immunity. Staying current on vaccines reduces infection burden, indirectly supporting marrow and overall resilience. OUP Academic
HSCT (curative intent in select ARO genotypes, not reliably in OSTM1). Reconstitutes osteoclasts from donor cells but does not halt neurodegeneration typical of OSTM1; selection is critical. PMC+1
Physical reconditioning. Regular, bone-safe PT improves cardiopulmonary reserve and immune resilience indirectly via better sleep and mobility. OUP Academic
Infection stewardship plans. Rapid assessment and treatment of fevers (“fever plan”) minimize immune exhaustion from uncontrolled infections. OUP Academic
Procedures/Surgeries
Hematopoietic stem cell transplantation (HSCT). Curative in some ARO genotypes by restoring osteoclast function; in OSTM1 ARO, neurologic decline typically persists, so transplant is often not recommended when CNS involvement is severe. Centers weigh risks/benefits case-by-case. PMC+2OUP Academic+2
Optic canal decompression (selected cases). Considered when imaging and exams show optic nerve compression correlating with rapidly worsening vision; done by experienced skull-base teams, with careful risk–benefit analysis. OUP Academic
Fracture fixation. Low-energy fractures are common due to brittle, sclerotic bone; surgical fixation uses techniques mindful of dense bone properties and healing challenges. OUP Academic
Dental/OMFS procedures. Timely drainage/extraction for dental abscesses to prevent jaw osteomyelitis; emphasize peri-procedural antibiotics and conservative techniques. OUP Academic
CSF shunting or decompression for raised intracranial pressure (rare, selected). Consider if skull thickening contributes to intracranial hypertension unresponsive to medical measures. OUP Academic
Preventions
Keep all vaccinations up to date; coordinate with specialists. OUP Academic
Prompt fever plans and early antibiotics for suspected bacterial infections. OUP Academic
Safe-handling routines to reduce fractures; avoid high-impact play. OUP Academic
Regular eye/ear checks to intercept compression early. OUP Academic
Dental hygiene and early care for tooth problems. OUP Academic
Home fall-proofing and use of appropriate mobility aids. OUP Academic
Nutrition tailored by a pediatric dietitian; avoid unsupervised high-dose calcium/vitamin D. OUP Academic+1
Anemia/platelet monitoring with scheduled CBCs. OUP Academic
Sleep and airway screening when snoring or apneas appear. OUP Academic
Early palliative/complex care involvement for symptom control and support. ScienceDirect
When to see a doctor urgently
Seek urgent care for fever, breathing difficulty, seizures, new severe headache/vomiting, sudden vision/hearing changes, unusual sleepiness, poor feeding/dehydration, major bruising/bleeding, or suspected fracture. These red flags reflect common OSTM1 ARO complications (infection, marrow failure, cranial nerve compression, and CNS progression) where early intervention changes outcomes. OUP Academic
What to eat and what to avoid
What to prioritize: Balanced pediatric diet with adequate protein, fruits/vegetables, whole grains, and calcium/vitamin D only to correct deficiency; hydration; iron-rich foods if iron-deficient. Work with dietitians to keep growth on track. OUP Academic
What to avoid: Megadoses of calcium or vitamin D without labs; unproven “bone-strengthening” supplements; high-impact chewables for children at dental risk; alcohol/adolescent vaping later in life—both undermine bone and immune health. OUP Academic+1
Frequently asked questions (FAQ)
Is there a cure for OSTM1-related ARO?
No. HSCT can cure many ARO types but often fails to stop neurologic decline in OSTM1 ARO, so benefit is limited. PMCWhat medicines treat it?
Only interferon gamma-1b is FDA-approved for malignant osteopetrosis and it delays progression; other drugs are supportive. FDA Access DataWhy are bones both “too hard” and “too fragile”?
Bone is dense because osteoclast resorption is defective, but the micro-architecture is abnormal, making it brittle and fracture-prone. PMCWhy does OSTM1 affect the brain?
OSTM1 is required for normal lysosomal function in neurons as well as osteoclasts; loss causes neurodegeneration. ScienceDirectCan we prevent vision or hearing loss?
Early surveillance helps; decompression may be considered in select cases, but outcomes vary. OUP AcademicIs calcitriol helpful?
Not for reversing ARO; translational data and experience do not support high-dose calcitriol to “activate” osteoclasts in this setting. PubMedShould every child get HSCT?
No—genotype and neurologic status guide decisions; OSTM1 ARO often does poorly after HSCT. PMCWhat is “disease progression” on the interferon label?
FDA labeling defines it using outcomes like falling hemoglobin/platelets, serious infections, hearing decline, or worse vision. actimmune.comDoes Actimmune improve X-rays or bone density?
It may modestly improve clinical course and marrow space in some patients, but it’s not curative; monitoring is essential. FDA Access DataAre there gene therapies?
Not currently available for OSTM1 ARO in clinical practice. Preclinical work continues on osteoclast biology. BioRxivHow common is OSTM1-related ARO?
All AROs are very rare; OSTM1 represents a small, severe subset with marked neurologic disease. PubMedWhat specialists should follow my child?
Pediatrics plus hematology, neurology, ophthalmology/ENT, dentistry, nutrition, PT/OT; add palliative/complex care early. OUP AcademicHow do we handle pain?
A combined approach (positioning, PT, safe medicines) tailored for nociplastic and musculoskeletal pain. Wiley Online LibraryWill my child grow normally?
Growth is often impaired by marrow failure, illness burden, and feeding difficulties; proactive nutrition helps. OUP AcademicWhere can clinicians find formal guidance?
Start with the Osteopetrosis Working Group consensus guidelines for diagnosis/monitoring/medical care and adapt for genotype and neurologic status. OUP Academic
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: October 12, 2025.
